Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies

References

• HCUPnet, Healthcare Cost and Utilization Project (2013) Agency for Healthcare Research and Quality. Available at: http://hcupnet.ahrq.gov/[Last accessed 28 June 2016]
   Google Scholar
• LaMori JC, Shoheiber O, Mody SH, Bookhart BK. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States. Clin Ther 2015;37:62-70
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Laliberté F, Nutescu EA, et al. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm 2012;18:363-74
   PubMedGoogle Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149:315-52
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160-98S
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Torbicki A, Agnelli G, et al.; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3033-69, 3069a-k
   PubMed Web of Science ®Google Scholar
• EINSTEIN-PE Investigators; Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
   PubMed Web of Science ®Google Scholar
• van Bellen B, Bamber L, Correa de Carvalho F, et al. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014;30:829-37
   PubMed Web of Science ®Google Scholar
• Gandhi SK, Salmon W, Kong SX, Zhao SZ. Administrative databases and outcomes assessment: An overview of issues and potential utility. J Manag Care Spec Pharm 1999;5:215-22
   Google Scholar
• Weeda ER, Peacock WF, Fermann GJ, et al. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract 2017;71. doi: 10.1111/ijcp.12915
   PubMed Web of Science ®Google Scholar
• Weeda ER, Wells PS, Peacock WF, et al. Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med 2017;12:311-18
   PubMed Web of Science ®Google Scholar
• Coleman CI, Fermann GJ, Weeda ER, et al. Is rivaroxaban associated with shorter hospital stays and reduced costs versus parenteral bridging to warfarin among patients with pulmonary embolism? Clin Appl Thromb Hemost 2016:1076029616661415
   Google Scholar
• Weeda ER, Kohn CG, Peacock WF, et al. Rivaroxaban versus heparin bridging to warfarin therapy: impact on hospital length of stay and treatment costs for low-risk patients with pulmonary embolism. Pharmacotherapy 2016;36:1109-15
   PubMed Web of Science ®Google Scholar
• Margolis JM, Deitelzweig S, Kline J, et al. Pulmonary embolism inpatients treated with rivaroxaban had shorter hospital stays and lower costs compared with warfarin. Clin Ther 2016;38:2496-503
   PubMed Web of Science ®Google Scholar
• Coleman CI, Baugh C, Crivera C, et al. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism. J Med Econ 2017;20:200-3
   PubMed Web of Science ®Google Scholar
• Kandilov A. Analysis report: estimating the incremental costs of hospital-acquired conditions (HACs). Centers for Medicare and Medicaid Services website. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/index.html [Last accessed 20 May 2016]
   Google Scholar
• Jeon CY, Neidell M, Jia H, et al. On the role of length of stay in healthcare-associated bloodstream infection. Infect Control Hosp Epidemiol 2012;33:1213-18
   PubMed Web of Science ®Google Scholar
• Bookhart BK, Haskell L, Bamber L, et al. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. J Med Econ 2014;17:691-5
   PubMedGoogle Scholar
• Kohn CG, Mearns ES, Parker MW, et al. Prognostic accuracy of clinical prediction rules for early post-pulmonary embolism all-cause mortality: a bivariate meta-analysis. Chest 2015;147:1043-62
   PubMed Web of Science ®Google Scholar
• Liu X, Johnson M, Mardekian J, et al. Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial. J Am Heart Assoc 2015;4
   Web of Science ®Google Scholar
• Desai A, Desai A, Calixte R, et al. Comparing length of stay between patients taking rivaroxaban and conventional anticoagulants for treatment of venous thromboembolism. Lung 2016;194:605-11
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Kline J, Margolis JM, et al. Comparison of rivaroxaban or warfarin use for venous thromboembolism on inpatient length of stay. J Am Coll Cardiol 2016;67:2065
   Web of Science ®Google Scholar
• Laliberté F, Pilon D, Raut MK, et al. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:645-53
   PubMed Web of Science ®Google Scholar
• Laliberté F, Cloutier M, Crivera C, et al. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther 2015;32:216-27
   PubMed Web of Science ®Google Scholar